Daily PubMed evidence board
Effect of depemokimab on asthma control and clinical outcomes: a systematic review and meta-analysis of randomized controlled trials.
This systematic review and meta-analysis pooled four randomized trials (total n≈954) testing depemokimab, a long-acting antibody against interleukin-5, in…
Signal score47Research triage score
CertaintyLowVerify in full text
PMID42268259Source identifier
Research triage, not medical advice
Do not use this summary, score, or benefit-cost estimate to diagnose, treat, prescribe, or change care without reviewing the full study and consulting qualified professionals.
Verify before acting
Check full-text methods, eligibility, outcomes, risk of bias, harms, conflicts, funding, replication, and applicability.
Plain-English signal
This systematic review and meta-analysis pooled four randomized trials (total n≈954) testing depemokimab, a long-acting antibody against interleukin-5, in patients with eosinophilic asthma. The drug was associated with a substantial reduction in asthma exacerbation rates (about half the rate versus placebo, IRR 0.47), but it did not produce a statistically significant improvement in symptom scores (ACQ-5) and did not meet the minimal important improvement for health-related quality of life (SGRQ). Reported safety was similar to placebo. The review protocol was registered on PROSPERO (CRD420261282685).
Why it matters
- Addresses depemokimab, a novel long-acting anti-IL-5 monoclonal antibody, for eosinophilic asthma - a population at high risk of exacerbations despite optimized therapy.
- Reports a large pooled effect on exacerbation rates (IRR 0.47), which is directly relevant to clinical outcomes, healthcare utilization, and guideline/coverage decisions for biologic therapies in severe eosinophilic asthma.
- Finds no significant improvement in symptom control (ACQ-5) or minimal important difference for quality of life (SGRQ), which affects how benefit is framed for patients and payers.
Primary outcomes
- Asthma Control Questionnaire-5 (ACQ-5)
- Asthma exacerbation rate
- St. George's Respiratory Questionnaire (SGRQ) - health-related quality of life
- Adverse events / safety
Effect summary
Pooled analysis of four RCTs (n=954) reported: no significant improvement in ACQ-5 (MD -0.30; 95% CI -0.92 to 0.32; I2=73.6%), a reduction in exacerbation rate (IRR 0.47; 95% CI 0.36 to 0.59; I2=0%), no clinically important improvement in SGRQ, and safety comparable to placebo.
Benefit-cost lens
| Quick take | Depemokimab appears to reduce exacerbations but not symptoms or quality-of-life beyond MCID; estimating value-for-money requires baseline exacerbation rates, per-patient costs of the drug and administration, and target population size. |
|---|---|
| BCR anchor | 1 |
| Time horizon | 3 |
| Discount rate | 0.03 |
| Assumptions | Summary and synthesis are based on four RCTs (n=954) reported in the abstract. Full-text verification needed for subgroup effects, absolute event rates, duration of follow-up, and cost-relevant inputs. |
Benefit-cost fields are assumptions-based unless explicitly source-derived. Treat them as prompts for deeper economic review.
Risk of bias
| Tool | abstract-based assessment (not a formal RoB tool) |
|---|---|
| Verdict | Higher uncertainty |
| Notes | Assessment based only on the abstract and metadata; heterogeneity for ACQ-5 (I2=73.6%) suggests variation across trials. Full-text is required to assess randomization, blinding, missing data, selective reporting, and other bias domains. |
Harms, equity, conflicts & implementation
| Implementation | Full-text evidence review, clinical eligibility definitions, cost and budget impact analysis, infusion/administration logistics (if applicable), and local guideline/coverage alignment. |
|---|---|
| Equity impact | Unclear from abstract; equity implications depend on eligibility criteria for biologic therapy, affordability, and differential access among populations with higher eosinophilic asthma burden. |
| Harms | Abstract reports safety comparable to placebo; detailed adverse-event profiles, rare harms, and long-term safety require full-text and postmarketing data. |
| Registration | CRD420261282685 |
| Replication | Unknown from abstract; replication and longer-term/real-world data not reported in the abstract. |
Source links — verify original
Use PubMed and full-text links to confirm methods, population, outcomes, harms, conflicts, and applicability.